AIM ImmunoTech ( (AIM) ) has released a notification of late filing.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
AIM ImmunoTech has announced a delay in filing its Form 10-Q (Quarter Report) for the financial period ending September 30, 2025. The delay is primarily due to the need for additional time to complete the necessary review and verification of data. The company expects to file the report within the permitted extension period. AIM ImmunoTech anticipates a decrease in revenues and net loss for the period compared to the previous year, with a notable reduction in net loss per share. The notification was signed by Robert Dickey IV, the Chief Financial Officer, who assured ongoing compliance efforts.
The most recent analyst rating on (AIM) stock is a Sell with a $1.50 price target. To see the full list of analyst forecasts on AIM ImmunoTech stock, see the AIM Stock Forecast page.
Spark’s Take on AIM Stock
According to Spark, TipRanks’ AI Analyst, AIM is a Underperform.
AIM ImmunoTech’s overall stock score is primarily impacted by its poor financial performance and bearish technical indicators. The company’s financial instability, characterized by negative equity and cash flow issues, is the most significant factor. The technical analysis further supports a negative outlook with indicators pointing to an oversold and downtrending stock. Valuation concerns, including a negative P/E ratio, also contribute to the low score.
To see Spark’s full report on AIM stock, click here.
More about AIM ImmunoTech
Average Trading Volume: 102,424
Technical Sentiment Signal: Sell
Current Market Cap: $3.9M
For a thorough assessment of AIM stock, go to TipRanks’ Stock Analysis page.